The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor
Open accessAbstract
High Resolution Image Download MS PowerPoint Slide KRAS G12D, the most common oncogenic KRAS mutation, is a promising target for the treatment of solid tumors. However, when compared to KRAS G12C, selective inhibition of KRAS G12D presents a significant challenge due to the requirement of inhibitors to bind KRAS G12D with high enough affinity to obviate the need for covalent interactions with the mutant KRAS protein. Here, we report the discovery and characterization of the first noncovalent, potent, and selective KRAS G12D inhibitor, MRTX1133, which was discovered through an extensive structure-based activity improvement and shown to be efficacious in a KRAS G12D mutant xenograft mouse tumor model.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MRTX1133 was identified via a structure-based drug design (SBDD) strategy as a potent, selective, and non-covalent KRAS G12D inhibitor directed at the switch II binding pocket.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [10]
In the citing paper
“It reversibly binds to activated and inactivated KRAS G12D protein to inhibit activity (25,26).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [25]
In the citing paper
“X-ray crystal structures of KRAS G12D /MRTX1133 co-complexed with GDP [10] and with GMPPCP, a non-hydrolysable GTP analog (Fig 1C and S1A), support the observed inhibitor potency in both active and inactive states of KRAS G12D .”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [10]
In the citing paper
“This drug discovery and lead optimization strategy culminated in the discovery of MRTX1133 as a KRAS G12D inhibitor with picomolar binding affinity and ~1,000-fold selectivity compared with KRAS WT , which is described in detail in Wang et al [10].”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [10]
In the citing paper
“MRTX1133 (30 mg/kg) was administered via intraperitoneal injection, twice per day, at the maximum in vivo tolerated dose as described by the manufacturer (30, 31), causing no significant cytotoxic side effects during treatment.”
From Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer (2024) · cites this paper as [31]
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors
Lanman, B. A., Allen, J. R., Allen, J. G., Amegadzie, A. K., Ashton, K. S., Booker, S. K., Chen, J. J., Chen, N., Frohn, M. J., Goodman, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01180 · Cited by 765
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Unrolling the hydrogen bond properties of C–H···O interactions
Steiner, T. (1997) · Chemical Communications · doi:10.1039/a603049a · Cited by 550
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Research works printed but not linked: 1
- Bos J. L., 1989, Cancer Res., 49, 4682
Cited by
Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment
Wood, L. D., Canto, M. I., Jaffee, E. M., & Simeone, D. M. (2022) · Gastroenterology · doi:10.1053/j.gastro.2022.03.056 · Cited by 865
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Metadata
- Authors
- Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., Hallin, J., Laguer, J., Lawson, J. D., Medwid, J., Newhouse, B., Nguyen, P., O’Leary, J. M., Olson, P., Pajk, S., Rahbaek, L., Rodriguez, M., Smith, C. R., Tang, T. P., Thomas, N. C., Vanderpool, D., Vigers, G. P., Christensen, J. G., & Marx, M. A.
- Affiliations
- Mirati Therapeutics (United States) (US)
- Pfizer (United States) (US)
- Mirati Therapeutics, San Diego, California 92121, United States
- Corresponding author
- Wang, Xiaolun
- Marx, Matthew A.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-12-10
- Volume
- 65
- Issue
- 4
- Pages
- 3123-3133
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4200173198
- Semantic Scholar
- 262ac67b588aeaf23909736c974e8fe8901c61b8
- Cited by
- 769
- References
- 31
- Citations by year
- 2026: 176 · 2025: 204 · 2024: 188 · 2023: 135 · 2022: 66
- FWCI
- 30.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1s10od021527-01)
- National Institute of General Medical Sciences (P30GM133894, P30GM124165)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- MRTX1133, KRAS G12D, KRAS inhibitors, non-covalent inhibitors, oncogenic KRAS, structure-based drug design, xenograft tumor model, solid tumors, small molecule inhibitors
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Models, Molecular, Mutation, Structure-Activity Relationship, Proto-Oncogene Proteins p21(ras), Xenograft Model Antitumor Assays, Mice, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor. https://app.cochat.ai/papers/10.1021/acs.jmedchem.1c01688
- The paper
- Wang, X., Allen, S., Blake, J. F., Bowcut, V., Briere, D. M., Calinisan, A., Dahlke, J. R., Fell, J. B., Fischer, J. P., Gunn, R. J., Hallin, J., Laguer, J., Lawson, J. D., Medwid, J., Newhouse, B., Nguyen, P., O’Leary, J. M., Olson, P., Pajk, S., . . . Marx, M. A. (2022). Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS G12D Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.1c01688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.